September 4, 2025
- APR Salud to become Positrigo distributor in Spain to sell and offer technical service for the NeuroLF system.
- Growing demand for brain PET imaging in Europe given the availability of disease-modifying therapies for Alzheimer’s disease.
Positrigo, a Swiss based company developing nuclear medical imaging devices to advance functional brain imaging, announced today its commercial expansion in Europe by appointing APR Salud as its distribution partner in Spain. The distribution agreement covers the sale of the NeuroLF system – a dedicated brain Positron Emission Tomography (PET) system – and all after sales activities including technical service in Spain.
After appointing distributors in Italy and France earlier this year, Positrigo continues to grow its commercial presence in Europe by entering a distribution arrangement with APR Salud in Spain. APR Salud is well established in Spain with a strong presence in the medical imaging field in general and nuclear medicine in particular. The company has a nationwide sale and a service team that has extensive experience in the commercialization of novel imaging technologies, training, education and after sales support.
“Similar to the US we see in Europe a positive momentum for the need of timely and accurate diagnosis of Alzheimer’s disease patients and are therefore expanding our commercial presence also in the EU. We are very happy to have with APR Salud a strong partner in Spain on board,” says Jannis Fischer, Chief Executive Officer at Positrigo. “APR Salud is an established company with a complementary product portfolio and a proven commercial track record.”
Just a few weeks ago the European Commission recommended the second disease-modifying therapy for Alzheimer’s disease for authorization1. The first treatment of similar kind received authorization this April2. Both therapies are supposed to increase significantly the demand for brain PET scans according to the Neuroimaging Committee of the European Association of Nuclear Medicine3.
“This alliance is fully aligned with our goal of making diagnostic imaging more accessible and innovative in everyday clinical practice. Our experience and consolidated network allow us to support each center from the identification of the initial technological need, through the complete installation and commissioning project, all the way to the efficient, optimized, and sustainable use of these systems, which make a real difference in the care of patients with neurological diseases”
Borja Ribed, CEO of APR Salud
Borja Ribed, CEO of APR Salud: “We are truly excited to count Positrigo among our strategic partners, but above all because this allows us to bring their innovative brain PET technology closer to healthcare professionals in our country. A technology that will enable early diagnosis and help improve the care and quality of life of patients. This alliance is fully aligned with our goal of making diagnostic imaging more accessible and innovative in everyday clinical practice. Our experience and consolidated network allow us to support each center from the identification of the initial technological need, through the complete installation and commissioning project, all the way to the efficient, optimized, and sustainable use of these systems, which make a real difference in the care of patients with neurological diseases”.
About Positrigo:
Positrigo is a pioneer in nuclear medical imaging technologies. Headquartered in Zurich, Switzerland, the medical device company was founded in 2018 as a spin-off of ETH Zurich. Positrigo’s technology, development, clinical testing and commercialization has been supported by various private investors, the Swiss government and the European Innovation Council. NeuroLF – the company’s first device – is an ultra-compact brain Positron Emission Tomography (PET) scanner which has applications in the assessment of causes of dementias, such as Alzheimer’s disease and other brain related disorders. NeuroLF is the first device of its kind with market authorization in the US and EU.
About APR Salud:
APR Salud is a 100% Spanish-owned company with more than 25 years of history, whose mission is to democratize technological solutions in the field of diagnostic imaging, with the aim of improving the quality of healthcare. After a long track record in maintaining diagnostic imaging equipment, in recent years the company has evolved into direct sales, partnering with leading international manufacturers and offering a comprehensive – and in some cases unique – solution in diagnostic imaging. Today, APR Salud has a presence throughout Spain with six regional offices, providing solutions in radiology, nuclear medicine, magnetic resonance imaging (MRI), and CT, among others.
References:
1 EMA recommends Kisnula for authorization in EU
2 EMA authorises Leqembi for treatment of early Alzheimer’s disease